What is happening with TRIPS?

Despite the importance of the TRIPS agreement, WTO members agreed to waive certain commitments to protect IP for COVID-19 vaccines in 2022. Now, the WTO is considering expanding that waiver to COVID-19 treatments. This would have immediate and lasting consequences for global health and America’s competitiveness, economic security and innovation leadership.

Biopharmaceutical innovators are calling on U.S. policymakers to reject an expanded IP waiver, and instead prioritize American patients, workers and innovation.  


Expanding the TRIPS waiver would:

illustration of a microscope

Jeopardize innovation

Many existing and investigational COVID-19 therapies are also useful for other diseases—ranging from cancer and HIV to autoimmune and neurological conditions such as Alzheimer’s, multiple sclerosis and Parkinson’s disease.

illustration of a syringe

Weaken American leadership

The United States is the global leader in biopharmaceutical innovation and production and led the way on developing COVID-19 technologies. An IP waiver effectively gives our valuable innovations to foreign entities.

illustration of a bar graph

Outsource American jobs

The U.S. biopharmaceutical industry supports 4.4 million American jobs. Forfeiting IP protections on valuable American technology will harm national and economic security and American jobs.

illustration of a clipboard

Hurt pandemic preparedness

The global IP system enabled America’s world-leading biopharmaceutical industry to innovate and produce safe and effective vaccines and treatments in record time. The waiver discourages the investment necessary to develop new technologies to combat COVID-19 and future health emergencies.


This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.